HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.

Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue PY, Van Natta ML, Meinert CL, Lederman MM, Hatano H, Jain V, Huang Y, Hecht FM, Martin JN, McCune JM, Moreno S, Deeks SG. · 2014

Read HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. by Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue PY, Van Natta ML, Meinert CL, Lederman MM, Hatano H, Jain V, Huang Y, Hecht FM, Martin JN, McCune JM, Moreno S, Deeks SG. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4022662.txt.

Introduction

Sergio Serrano-Villar and a large team of co-authors study a T cell balance marker in people with HIV on treatment, in PLoS Pathogens in 2014. Antiviral therapy can restore helper T cell counts to normal, yet some patients keep a low ratio of helper to killer T cells. In older adults without HIV, a low ratio tracks with more illness and death.

Drawing on four patient groups and three trials, the team profiled such patients. Their T cells skewed toward worn, late-stage forms, with higher activation and ageing marks. Gut tissue mirrored the blood pattern, while lymph nodes did not. Starting therapy within months of infection lifted the ratio far more than starting years later. After accounting for age, treatment length, and cell counts, a low ratio still foretold more illness and death. The authors propose it as a watch marker.

Catalog record

CREATORSerrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue PY, Van Natta ML, Meinert CL, Lederman MM, Hatano H, Jain V, Huang Y, Hecht FM, Martin JN, McCune JM, Moreno S, Deeks SG.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE69 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4022662

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality By Sergio Serrano-Villar, Talia Sainz, Sulggi A Lee, Peter W Hunt, Elizabeth Sinclair, Barbara L Shacklett, April L Ferre, Timothy L Hayes, Ma Somsouk, Priscilla Y Hsue, Mark L Van Natta, Curtis L Meinert Published in: PLoS Pathogens DOI: 10.1371/journal.ppat.1004078 ABSTRACT Abstract A low CD4/CD8 ratio in elderly HIV-uninfected adults is associated with increased morbidity and mortality. A subset of HIV-infected adults receiving effective antiretroviral therapy (ART) fails to normalize this ratio, even after they achieve normal CD4+ T cell counts. The immunologic and clinical characteristics of this clinical phenotype remain undefined. Using data from four distinct clinical cohorts and three clinical trials, we show that a low CD4/CD8 ratio in HIV-infected adults during otherwise effective ART (after CD4 count recovery above 500 cells/mm3) is associated with a number of immunological abnormalities, including a skewed T cell phenotype from naïve toward terminally differentiated CD8+ T cells, higher levels of CD8+ T cell activation (HLADR+CD38+) and senescence (CD28− and CD57+CD28−), and higher kynurenine/tryptophan ratio. Changes in the peripheral CD4/CD8 ratio are also reflective of changes in gut mucosa, but not in lymph nodes. In a longitudinal study, individuals who initiated ART within six months of infection had greater CD4/CD8 ratio increase compared to later initiators (>2 years). After controlling for age, gender, ART duration, nadir and CD4 count, the CD4/CD8 ratio predicted increased risk of morbidity and mortality. Hence, a persistently low CD4/CD8 ratio during otherwise effective ART is associated with increased innate and adaptive immune activation, an immunosenescent phenotype, and higher risk of morbidity/mortality. This ratio may prove useful in monitoring response to ART and could identify a unique subset of individuals needed of novel therapeutic interventions. INTRODUCTION It is now anticipated that HIV-infected adults who have access to modern antiretroviral therapy (ART) should be able to suppress HIV replication indefinitely. Although treatment-mediated increases in the peripheral CD4 count are associated with reduced morbidity and mortality, compared to age-matched individuals without HIV infection, those on ART have a higher risk of morbidity and mortality. This risk is predicted in part by the on therapy CD4 count, although achieving an apparent normal CD4 count may not fully restore health [1]–[5]. Indeed, it has been shown that even those treated patients with CD4+ T cell counts above 500 cells/mm3, a further CD4+ T cell count increase is still associated with a slight benefit in terms of mortality [6]. The decreased life expectancy during ART-mediated viral suppression is largely explained by a higher than expected risk of non-AIDS-morbidity, a term that entails a group of conditions generally associated with aging, including cardiovascular, renal, liver, neurologic, and bone disease, as well as cancer [4], [7], [8]. While the mechanisms driving the increased burden of aging-associated disease in HIV-infected individuals are not fully understood, an emerging body of evidence suggests that persistent innate and adaptive immune dysfunction and/or activation are major risk factors [9]–[12]. Many of the immunologic abnormalities that persist during therapy are similar to those observed in the elderly, raising the hypothesis that age-associated decline in immune function (“immunosenescence”) contributes to disease progression and adverse outcomes [13]–[16]. Markers of innate immune activation [e.g. interleukin (IL)-6, high-sensitivity C reactive protein (hs-CRP) and soluble CD14 (sCD14)], coagulation (fibrinogen, D-dimers), bacterial translocation (lipopolysaccharide), and T cell activation (HLADR and CD38 co-expression) are elevated despite effective ART and associated with subsequent morbidity and mortality, even after adjustment for CD4+ T cell count [17]–[21]. Induction of indoleamine 2,3-dioxygenase-1 (IDO) in monocytes and dendritic cells occurs during HIV infection and has been associated with impairment of the mucosal immunity and the maintenance of a chronic inflammatory state [22]. Collectively, these observations strongly suggest that an underlying mechanism not captured by CD4+ T cell count and HIV replication might be contributing to disease progression. The importance of CD4 counts as a strong predictor of opportunistic infections and non-AIDS events has been widely investigated, but little attention has been paid to the prognostic significance of CD8 counts. During untreated HIV infection, CD8 counts increase as CD4 counts decline [23]. During ART-mediated viral suppression, some individuals achieving CD4 counts above 500 cells/mm3 experience a simultaneous decline in CD8 counts, leading to normalization of the CD4/CD8 ratio. Others, however, maintain high levels of circulating CD8+ T cells, and hence a persistently low CD4/CD8 ratio [24]. Among elderly HIV-uninfected adults, inversion of the CD4/CD8 ratio (<1.0) predicts all-cause mortality and is considered part of the immunosenescent phenotype [25]–[29]. In the setting of untreated HIV infection, the CD4/CD8 ratio predicts time to AIDS [30] and is associated with pre-ART CD4 and CD8 counts [24], [31]. Among treated adults with spectrum of CD4+ T cell counts, the ratio appears to correlate with markers of T cell activation and senescence [32], [33] and with the risk of non-AIDS morbidity and mortality [34]–[36]. Whether this is true in those with normalized CD4+ T cell counts is unknown. We hypothesized that among ART-treated HIV-infected individuals with CD4 counts ≥500 cells/mm3, expansion of CD8+ T cells, reflected as a low CD4/CD8 ratio, may identify individuals with persistent innate and adaptive immune activation at greater risk of serious non-AIDS events. Since early ART initiation has been shown to reduce levels of T cell activation, we hypothesized that earlier ART initiation might also accelerate the rate of CD4/CD8 ratio normalization. METHODS Subjects Study subjects were sampled from four cohorts and two clinical trials: 1) SCOPE: a clinic-based cohort of over 1500 chronically HIV-infected participants and HIV-uninfected controls in San Francisco; 2) the Study of the Ocular Complications of AIDS (SOCA): a multicenter cohort of over 2200 HIV-infected participants who initiated ART with an AIDS diagnosis; 3) OPTIONS: a clinic-based cohort of participants diagnosed during acute/early HIV infection, previously described [37]; 4) the Madrid cohort: a clinic-based cohort of 2400 ART-treated individuals, 130 of whom developed serious non-AIDS events. 5) the raltegravir (NCT00631449) [38] and maraviroc (NCT00735072) [39], [40] ART intensification randomized, placebo-controlled, clinical trials in HIV-infected individuals. Additional information on the cohorts and the clinical trials can be found in Text S1. Ethics statement These studies were approved by the UCSF Committee on Human Research or by the Ethics Committee of the University Hospital Ramón y Cajal. All participants were adults and provided written informed consent in accordance with the Declaration of Helsinki. Measurements T cell immunophenotyping was performed on cryopreserved peripheral blood mononuclear cells (PBMC), in fresh lymph node mononuclear cells (LNMC) from inguinal biopsies obtained from HIV-infected volunteers under ART-mediated viral suppression, and in mucosal mononuclear cells (MMC) obtained from rectal biopsies in the maraviroc and raltegravir studies, as previously described [38], [39], [41]. Fresh inguinal lymph nodes were biopsied were minced and strained through a 70 micron filter to created a single cell suspension of LNMC. MMC were isolated from biopsy specimens using a protocol optimized for lymphocyte viability and yield [42]. Cells were thawed, washed, stained with LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen) to exclude non-viable cells and stained with fluorescently-conjugated monoclonal antibodies (recognizing CD3, CD4, CD8, HLADR, CD38, CD27, CD28, CCR5, CCR7, CD45, PD1 for PBMC and

Read the complete text